Results for "antiviral"
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen
First published: 29 October 2018
LATTE-2 study shows high rates of virologic response and long-term durability with the long-acting, injectable, two-drug regimen over 160 weeks
ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine
First published: 16 November 2018
Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion on a Type II variation regulatory application for Tivicay (dolutegravir).
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare
First published: 26 November 2018
The Ministry of Health, Labour and Welfare (MHLW) has approved Juluca Combination Tablets for the maintenance treatment of human immunodeficiency virus type 1 (HIV-1) infection.
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV
First published: 29 July 2019
The marketing application is based on phase III ATLAS and FLAIR pivotal trials in which the once-monthly, injectable treatment regimen showed similar efficacy and safety to daily, 3-drug oral treat...
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV
First published: 06 November 2019
Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations, and look deeper into its 2-drug regimen studies
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
First published: 13 December 2019
If approved, DTG will be the first integrase inhibitor available as a dispersible tablet for children living with HIV.
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen
First published: 08 October 2020
The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s well-established safety and tolerability profile
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
First published: 15 July 2019
Data to be presented span the company’s diverse portfolio, challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living with HIV
ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen
First published: 19 December 2016
First phase III studies to show efficacy of two-drug regimen as maintenance therapy
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
First published: 16 October 2020
Long-acting regimen is based on co-administration of cabotegravir and rilpivirine injections once-monthly or once every 2-months